Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol. 2020;13:143.

Article  PubMed  PubMed Central  Google Scholar 

Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.

Article  PubMed  PubMed Central  Google Scholar 

Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer. 2022;170:41–51.

Article  PubMed  Google Scholar 

Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014;15:1–6.

Article  PubMed  Google Scholar 

Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013;79:33–9.

Article  PubMed  Google Scholar 

Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus Bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer Jan. 2021;151:20–4.

Article  Google Scholar 

Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus Bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. The Lancet. Oncol May. 2019;20(5):625–35.

Google Scholar 

Zhou Q, Xu CR, Cheng Y et al. Bevacizumab plus Erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study.

Long J, Lei S, Wu Z, Xiong S, Wang C, Huang L, et al. Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study. Ann Transl Med. 2022;10:1334.

Article  PubMed  PubMed Central  Google Scholar 

Yu Y, Wang Y, Wu L, Xu X, Zhou H, Wang Q, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: a cohort study. Med (Baltim). 2021;100:e23712.

Article  Google Scholar 

Xu Z, Teng F, Hao X, Li J, Xing P. Bevacizumab Combined with continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression. Cancer Manag Res. 2022;14:1891–902.

Article  PubMed  PubMed Central  Google Scholar 

Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z, et al. Anlotinib plus Icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study. Mol Cancer. 2023;22:124.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Fang W, Yu Q, Zhang H, Wu G, Wu D, et al. LBA10 A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER). Ann Oncol. 2022;33:S1562.

Article  Google Scholar 

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced Non-small Cell Lung Cancer: the ALTER 0303 phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4:1569–75.

Article  PubMed  PubMed Central  Google Scholar 

Zhang C, Cao H, Cui Y, Jin S, Gao W, Huang C, et al. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021;12:2574–84.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Jiang N, Liang X, Chen N, Chen Y, Zhang C, et al. Low–dose anlotinib combined with EGFR–TKI can be used as an alternative for EGFR–TKI–resistant non–small cell lung cancer in elderly patients. Oncol Lett. 2023;26:323.

Article  PubMed  PubMed Central  Google Scholar 

Wang M, Zhao J, Chen T, Hu X, Wang L, Shi Y, et al. Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance. Thorac Cancer. 2023;14:873–80.

Article  PubMed  PubMed Central  Google Scholar 

Zhou B, Gong Q, Li B, Qie HL, Li W, Jiang HT, et al. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: a retrospective study. J Clin Pharm Ther. 2022;47:643–51.

Article  PubMed  Google Scholar 

Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis. 2018;10:S2537–44.

Article  PubMed  PubMed Central  Google Scholar 

Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond Response Evaluation Criteria in Solid Tumors Progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung Cancer: the ASPIRATION Study. JAMA Oncol. 2016;2:305–12.

Article  PubMed  Google Scholar 

Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–61.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Yao Y, Xu Y, Li L, Gong Y, Zhang K, et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat Commun. 2021;12:11.

Article  PubMed  PubMed Central  Google Scholar 

Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.

Article  PubMed  PubMed Central  Google Scholar 

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

Article  PubMed  PubMed Central  Google Scholar 

Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–92.

Article  PubMed  Google Scholar 

Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol. 2016;27:417–23.

Article  PubMed  Google Scholar 

Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–8.

Article  PubMed  Google Scholar 

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, et al. Gefitinib Plus Chemotherapy Versus Chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell Lung Cancer resistant to First-Line Gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017;35:4027–34.

Article  PubMed  Google Scholar 

Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33:466–87.

Article  PubMed  Google Scholar 

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389:1935–48.

Article  PubMed  Google Scholar 

Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS et al. Amivantamab plus Lazertinib in previously untreated EGFR-Mutated Advanced NSCLC. N Engl J Med.2024.

Li YS, Jie GL, Wu YL. Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Ther Adv Med Oncol. 2023;15:17588359231193726.

Article  PubMed  PubMed Central  Google Scholar 

Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.

Article